Home » Posts tagged 'PMNOC'

PMNOC

IP Intensive Program: Experiential Learning at Actavis

My 10 week internship at Actavis’ Canadian arm (formerly known as Cobalt), through Osgoode’s IP Intensive Program coincided with a very exciting time for the company. The company recently expanded through a number of acquisitions to make it the third-largest generic pharmaceutical company globally, with commercial operations in more than 60 countries worldwide.

Canada’s Top Court Gives Canadians Something to Get Excited About, Generic Viagra!

On November 8, 2012 the Supreme Court of Canada (SCC) released its eagerly anticipated decision in the “Viagra Appeal”. In a unanimous decision written by Justice LeBel, the SCC found the patent at issue invalid for insufficient disclosure. This decision marks the end of a lengthy legal battle between Teva and Pfizer over the validity […]

Federal Court of Appeal’s Decision Interpreting Section 8 of the Patented Medicines (Notice of Compliance) Regulations Leads to Mixed Results

The Federal Court of Appeal has recently released its first decision interpreting Section 8 of the Patented Medicines (Notice of Compliance) Regulations [PM(NOC)]. The PM(NOC) Regulations essentially serve as a link between the patent system and the drug regulatory approval system. The Regulations enhance protection for pharmaceutical patents by requiring generic companies to “clear” relevant […]